- Home
- VRAX vs ACON Comparison
VRAX vs ACON Comparison
Compare VRAX & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VRAX
- ACON
- Stock Information
- Founded
- VRAX 2013
- ACON 2008
- Country
- VRAX United Kingdom
- ACON United States
- Employees
- VRAX N/A
- ACON N/A
- Industry
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- ACON Retail: Computer Software & Peripheral Equipment
- Sector
- VRAX Health Care
- ACON Technology
- Exchange
- VRAX Nasdaq
- ACON Nasdaq
- Market Cap
- VRAX 4.4M
- ACON 4.5M
- IPO Year
- VRAX 2022
- ACON 2022
- Fundamental
- Price
- VRAX $0.75
- ACON $7.05
- Analyst Decision
- VRAX Strong Buy
- ACON Buy
- Analyst Count
- VRAX 1
- ACON 2
- Target Price
- VRAX $3.00
- ACON $481.00
- AVG Volume (30 Days)
- VRAX 132.3K
- ACON 12.3K
- Earning Date
- VRAX 01-01-0001
- ACON 08-14-2025
- Dividend Yield
- VRAX N/A
- ACON N/A
- EPS Growth
- VRAX N/A
- ACON N/A
- EPS
- VRAX N/A
- ACON N/A
- Revenue
- VRAX $6,331.00
- ACON $62,948.00
- Revenue This Year
- VRAX $217,274.83
- ACON $145.39
- Revenue Next Year
- VRAX N/A
- ACON $145.45
- P/E Ratio
- VRAX N/A
- ACON N/A
- Revenue Growth
- VRAX N/A
- ACON 16.68
- 52 Week Low
- VRAX $0.72
- ACON $6.20
- 52 Week High
- VRAX $9.00
- ACON $3,499.51
- Technical
- Relative Strength Index (RSI)
- VRAX 38.90
- ACON 49.81
- Support Level
- VRAX $0.72
- ACON $7.00
- Resistance Level
- VRAX $0.80
- ACON $7.52
- Average True Range (ATR)
- VRAX 0.07
- ACON 0.41
- MACD
- VRAX -0.01
- ACON 0.00
- Stochastic Oscillator
- VRAX 10.07
- ACON 54.64
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes (HSV-1) and Human Papillomavirus (HPV).
About ACON Aclarion Inc.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), and a proprietary biomarker to optimize clinical treatments. Its product Nociscan is a SaaS platform that leverages MR Spectroscopy to noninvasively help physicians distinguish between painful and nonpainful discs in the spine. The company derives its revenues from one source, the delivery of Nociscan reports to medical professionals. Substantially all revenues are generated from contracts with customers in the United States.